RASGRP2 promotes doxorubicin chemoresistance and tumor progression in osteosarcoma via the Notch1-NICD-Hes1 axis.
BACKGROUND Doxorubicin (DOX) resistance remains a major obstacle to favorable outcomes in osteosarcoma. The role of RASGRP2 in osteosarcoma chemoresistance is poorly understood. METHODS We analyzed RASGRP2 expression and prognostic value across pan-cancer datasets (TCGA, TARGET) and osteosarcoma cohorts (TARGET-OS, G...